Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas

NCT03181477 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2017-04-07
Last updated
2025-02-17

Condition(s) studied

Glioblastoma, Adult

Investigational drug(s) / intervention(s)

Radiotherapy

Radiotherapy: Radiotherapy of 80 GY + Chemotherapy (Temozolomide)

Study summary

Glioblastoma (GBM) is the most aggressive and most frequent brain tumour. Approximately four people per 100,000 inhabitants are diagnosed with this disease every year. The standard treatment comprises surgical resection (whenever possible), normofractionated radiotherapy at a dose of 60Gray (Gy) and temozolomide (TMZ). Median overall survival in these patients is 14.6 months \[13.2-16.8\].

In a previous phase I clinical trial, dose escalation tolerance using simultaneous-integrated boost intensity-modulated radiation therapy (SIB-IMRT) technic has been evaluated. The investigator demonstrated that SIB-IMRT until a dose of 80Gy in 32 daily fractions, associated with TMZ is feasible and well tolerated by patients with glioblastoma.

The aim of this present phase II clinical trial is to evaluate the overall survival at 18 months for patients with glioblastoma receiving TMZ, according to standard protocol, associated to radiotherapy delivered at 80Gy using SIB-IMRT technic. The first planning target volume (PTV), including oedema and tumour highlighted on T2 flair magnetic resonance imaging (MRI) sequences, will receive 60.8Gy in 32 daily fractions. The second PTV, including tumour highlighted on T1 MRI sequences, will receive 80.0Gy in 32 daily fractions.

Secondary objectives are tolerance, survival free progression and quality of live evaluations.

Sixty seven patients will be enrolled in this present trial.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged from 18 to 70 years old. * Patients with a unifocal Glioblastoma (grade IV astrocytoma in the World Health Organization (WHO) classification) with postoperative macroscopic residue after biopsy or resection alone. * Location of the tumor or residual tumor, detected by Magnetic Resonance Imaging (MRI) sequences T1 gadolinium, more than 1cm from the optic chiasm * Diagnosis confirmed by pathology. * Time from surgery (if performed) and the start of radiation therapy less than 6 weeks. * performance status 0 or 1 in the WHO classification. * methylation status of the MGMT promoter gene requested * blood count: Neutrophil more than 1500/mm3 Platelets more than 100 000/mm3 * Liver function test Bilirubin less than 1,5 times upper limit transaminases than 3 times upper limit * patient informed and informed consent signed * Possibility to trat by radiation withintensity modulated (fixed beams modulated or rotational modulation (TomoTherapy, dynamic arctherapy)) strictly respecting the constraints to organs at risk (Crystalline: 8 Gy max, Posterior chamber of the eye: 45 Gy max , optic nerve: 54 Gy max, chiasm: 54 Gy max, brain Stem: 2% 58 Gy D2 \<64 Gy, Dmax \<69 Gy spinal cord: 46 Gy max, healthy brain (brain - PTV): 60 Gy max 33%, 50 Gy to 50% and D100 \<45 Gy to the brain in toto). * The patient must be affiliated to a social security scheme. Exclusion Criteria: * Other histological "Glioblastoma". * Excision macroscopically complete individualized on postoperative MRI. * Patient unable to give consent. * A patient with against-indication to performed MRI (pacemaker, uncontrollable claustrophobia ...). * The patient must not have received radiation therapy or previous chemotherapy for this condition. * Other neoplasia unstabilized and / or treated for less than 5 years. * Patient already included in another clinical trial with an experimental molecule. * Inability to submit to medical monitoring testing for geographical, social or psychological. * Pregnancy or breastfeeding * Private Person of liberty under supervision or under curatorship * No affiliation to a social security scheme or medical state aid or the universal medical coverage

Primary outcome measure(s)

  • Overall survival — 18 months

Trial sites (7)

FacilityCityRegionStatus
CHU Amiens Picardie Amiens France
CHU Besançon Besançon France
Centre Georges François Leclerc Dijon France
Centre d'oncologie et de radiothérapie Mâcon France
Institut de cancérologie de Lorraine Nancy France
Paul Strauss Strasbourg France
Centre de cancérologie des dentellières Valenciennes France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03181477 on ClinicalTrials.gov ↗ ← All trials in France